Andrew Wei

Personal profile

Biography

Dr Andrew Wei is a Victorian Cancer Agency Research Fellow and Haematologist at the Alfred Hospital. Andrew conducts clinical and translational AML research through dual appointments at the Alfred Hospital and Monash University.

After completing doctoral studies at the Walter and Eliza Hall Institute of Medical Research in 2005, he joined the Alfred Hospital in 2008 to develop the AML research program. He has been the AML disease group chairperson for Australasian Leukaemia and Lymphoma Group since 2009 and has led multiple nationwide cooperative group studies as chief investigator. His doctoral research studies contributed to discoveries elucidating the functional interaction between Bcl-2 family members (Molecular Cell 2005;17(3):393-403), the role of Mcl-1 in cancer susceptibility to ABT-737 (Cancer Cell. 2006;10(5):389-99) and the pro-survival function of the EBV Bcl-2 homologue BHRF-1 (PLoS Pathogens 2010;6[12]).

Dr Wei is an executive member of the ALLG Scientific Advisory Committee, a member of the National Medical and Scientific Advisory Committee of the Leukaemia Foundation of Australia and Head of Leukaemia Research at the Alfred hospital. He sits on the International Steering Committee for Celgene providing expert advice on AML. To enhance translational research, Dr Wei has established the Alfred Haematology Tissue Bank, the diagnostic molecular haematology laboratory and a pre-clinical research laboratory to focus on the role of targeting survival pathways in AML.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2009 2023

1 Not started
14 Finished
15 Active

Integrated Management of Post Remission Leukaemia to Optimise longevity and Enhance Quality of Life

Wei, A., Fleming, S. A. & Rady, K.

14/03/19 → 30/05/22

Project: Research

A Phase III, Double-Blind. Placebo-Controlled, Multicenter, Randomized Study of Pracinostat in Combination with Azacitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia unfit for Standard Induction Chemotherapy.

Wei, A. & Kennedy, N.

4/03/19 → 31/10/23

Project: Research

Improving survival in myelofibrosis

Perkins, A., Ross, D., Lane, S., Forsyth, C., Wei, A., Curtis, D., Shortt, J., Erber, W. N. & Stevenson, W. S.

The Department of Health (Comm)

3/01/19 → 31/12/23

Project: Research

An International Phase Ib multicentre study to characterize the safety and tolerability of intravenously administered S64315, a selective Mcl-1 inhibitor, in combination with orally administered venetoclax, a selective Bcl-2 inhibitor, in patients with Acute Myeloid Leukaemia (AML).

Wei, A. & Kennedy, N.

23/10/18 → 23/10/22

Project: Research

A Phase 1, 2-Part, Multicenter, Open-label, 3-Arm Study to Determine the effect of Enasidenib (CC-90007) on the Pharmacokinetics of Single Doses of Caffeine, Dextromethorphan, Flurbiprofen, Midazolam, Omeprazole, Digoxin, Rosuvastatin, and Pioglitazone in Subjects with Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation.

Wei, A. & Kennedy, N.

12/10/18 → 12/10/23

Project: Research

Research Output 2008 2018

56 Article
14 Letter
4 Comment / Debate
2 Review Article
1 More
- 1 Poster

Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies

Tiong, I. S., Reynolds, J., Bradstock, K. F., Seymour, J. F., Wei, A. H. & on behalf of the Australasian Leukaemia & Lymphoma Group, 22 Aug 2018, In : Blood Cancer Journal. 8, 9, 5 p., 84.

Research output: Contribution to journal › Article › Research › peer-review

Open Access

File

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1

Teh, T. C., Nguyen, N. Y., Moujalled, D. M., Segal, D., Pomilio, G., Rijal, S., Jabbour, A., Cummins, K., Lackovic, K., Blombery, P., Thompson, E., Ekert, P. G., Lessene, G., Glaser, S. P., Huang, D. C. S., Roberts, A. W., Guthridge, M. A. & Wei, A. H., 1 Feb 2018, In : Leukemia. 32, 2, p. 303-312 10 p.

Research output: Contribution to journal › Article › Research › peer-review

Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia

Tiong, I. S., Tan, P., McManus, J., Cummings, N., Sadawarte, S., Catalano, J., Hills, R. & Wei, A., 2018, In : Leukemia and Lymphoma. 59, 2, p. 493-496 4 p.

Research output: Contribution to journal › Letter › Research › peer-review

Accelerating Early Drug Development: Come on Down Under

Wei, A., Jul 2017, In : Annals of Oncology. 28, 7, p. 1655-1657 3 p., mdx101.

Research output: Contribution to journal › Article › Other › peer-review

Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia

Kantarjian, H. M., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J. M., Wei, A., Dombret, H., Foà, R., Bassan, R., Arslan, Ö., Sanz, M. A., Bergeron, J., Demirkan, F., Lech-Maranda, E., Rambaldi, A., Thomas, X., Horst, H-A., Brüggemann, M., Klapper, W. & 6 othersWood, B. L., Fleishman, A., Nagorsen, D., Holland, C. J., Zimmerman, Z. & Topp, M. S., 2 Mar 2017, In : New England Journal of Medicine. 376, 9, p. 836-847 12 p.

Research output: Contribution to journal › Article › Research › peer-review

Prizes

2003: Albert Baikie Award, Best Oral Abstract Presentation, Haematology Society of Australia

Andrew Wei (Recipient), 2004

Prize: Prize (including medals and awards)

2003: Young Investigator Award, Best Oral Abstract Presentation, Annual Scientific Meeting, Hobart

Andrew Wei (Recipient), 2003

Prize: Prize (including medals and awards)

2004: New Investigator Award, Best Oral Abstract, Annual Scientific Meeting, Canberra

Andrew Wei (Recipient), 2004

Prize: Prize (including medals and awards)

Activities 2012 2012

8 Membership of an advisory panel/policy group/ board